Thermo Fisher Scientific Inc (TMO) Financial Statements

Thermo Fisher's financial health presents a mixed picture when evaluated through the GoodMoat Quality Indicators. The company is GAAP profitable with a 15.0% profit margin and a 17.4% operating margin, indicating solid core earnings. The balance sheet is reasonably healthy with a Debt/Equity ratio of 0.74, which is below the framework's cautionary threshold of 1.0x Debt/EBITDA, suggesting manageable leverage. However, several metrics are neutral or modest relative to high-quality benchmarks. The Return on Equity of 12.6% is below the framework's high-quality threshold of 15-20% for ROIC. Revenue growth of 7.2% YoY is consistent but not double-digit, placing it in a lower growth trajectory. The Free Cash Flow yield of 3.4% implies a P/FCF multiple near 29x, which is not low, and converting this to a margin suggests an FCF margin likely below the 10-15% framework target. From a Growth Assessment perspective, the 7.2% growth is sustained but not accelerating, and it is driven by the company's scale and market position rather than explosive new drivers. For a value investor, the quality is adequate with a strong balance sheet and profitability, but the growth rate and cash flow generation are moderate, which may not fully support a premium valuation multiple without clearer signs of operating leverage or margin expansion.